Analisis Efektivitas Biaya Terapi Antihipertensi Pada Pasien Hipertensi Rawat Inap Di Rumah Sakit Umum Daerah Dr. Moewardi Tahun 2014
Daftar Isi:
- Hypertension is a major risk factor for heart disease such as myocardial infarction, stroke, heart failure and death. Health financing in Indonesia has increased. Cost-effectiveness analysis is needed to assist in decision these medicines are effective in benefits and costs. This study aims to determine the direct medical costs and analyze cost-effective of antihypertensive drug for hypertensive patients hospitalized in the Hospital Dr.Moewardi Surakarta in 2014. This research is non-experimental research with descriptive design. The data taken is retrospective data carried out in the Hospital Dr. Moewardi based medical records. Data were taken for analysis of cost-effectiveness is data antihypertensive therapy effectiveness and direct medical costs. The results showed, the smallest direct medical costs incurred by patients using a combination of ACEI-Diuretics on inpatient unit class III with direct medical costs of Rp903.481,62. The largest direct medical costs incurred by patients using ARB-diuretic combination on the VIP ward with direct medical costs of Rp6.896.247,00. The most cost effective antihypertensive therapy based on ACER is a combination of ACEI-BB used by patients in the inpatient unit class III with a value of ACER Rp10.180,36. The most cost-effective antihypertensive therapy by ICER for each inpatient unit is, ACEI-BB for inpatient room class III, CCB-BB to patients in the inpatient unit Class II, CCB-diuretics for patients in the VIP ward, and ACEI-diuretics for patients in intensive care